Anavex Life Sciences Corp (AVXL)

[falconer66a]

The 80% Factor

A key finding revealed in the PDF:

Majority of AD population, about 80% has no variant SIGMAR1 gene, hence the majority of patients is expected to benefit from ANAVEX®2-73.

About 80% of Alzheimer’s patients would then be expected “...to have improved benefit from ANAVEX®2-73.”

If there are 5.5 million Americans with Alzheimer’s, Anavex will be able to treat only 80% of those, about 4.4 million.

Plug that number into your potential Anavex revenues calculation.